Cargando…
Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE‐TPA): A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Study
OBJECTIVE: Otaplimastat is a neuroprotectant that inhibits matrix metalloprotease pathway, and reduces edema and intracerebral hemorrhage induced by recombinant tissue plasminogen activator (rtPA) in animal stroke models. We aimed to assess the safety and efficacy of otaplimastat in patients receivi...
Autores principales: | Kim, Jong S., Lee, Kyung Bok, Park, Jong‐Ho, Sung, Sang Min, Oh, Kyungmi, Kim, Eung‐Gyu, Chang, Dae‐il, Hwang, Yang Ha, Lee, Eun‐Jae, Kim, Won‐Ki, Ju, Chung, Kim, Byung Su, Ryu, Jei‐Man |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003891/ https://www.ncbi.nlm.nih.gov/pubmed/31721277 http://dx.doi.org/10.1002/ana.25644 |
Ejemplares similares
-
tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?
por: Kim, Jong S.
Publicado: (2019) -
tPA or not tPA? Lysis therapy in the setting of COVID‐19 and ECMO
por: Cromartie, Anjelica, et al.
Publicado: (2022) -
To tPA or Not to tPA: Two Medical-Legal Misadventures of Diagnosing a Cerebrovascular Accident as a Stroke Mimic
por: Moore, Malia J., et al.
Publicado: (2019) -
Unintentional intramuscular administration of tPA/DNase for pleural infection
por: Popowicz, Natalia, et al.
Publicado: (2014) -
Intravenous tPA for Acute Ischemic Stroke in Patients with COVID-19
por: Carneiro, Thiago, et al.
Publicado: (2020)